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Abstract
The rate of senescence can be inferred from the acceleration by which mortality rates increase over age. 
Such a senescence rate is generally estimated from parameters of a mathematical model fitted to these 
mortality rates. However, such models have limitations and underlying assumptions. Notably, they do 
not fit mortality rates at young and old ages. Therefore, we developed a method to calculate senescence 
rates from the acceleration of mortality directly without modeling the mortality rates. We applied the 
different methods to age group–specific mortality data from the European Renal Association—European 
Dialysis and Transplant Association Registry, including patients with end-stage renal disease on dialysis, 
who are known to suffer from increased senescence rates (n = 302,455), and patients with a functioning 
kidney transplant (n = 74,490). From age 20 to 70, senescence rates were comparable when calculated 
with or without a model. However, when using non-modeled mortality rates, senescence rates were 
yielded at young and old ages that remained concealed when using modeled mortality rates. At young 
ages senescence rates were negative, while senescence rates declined at old ages. In conclusion, 
the rate of senescence can be calculated directly from non-modeled mortality rates, overcoming the 
disadvantages of an indirect estimation based on modeled mortality rates.
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Across populations and species, actuarial mortality rates exhibit dif-
ferent age patterns (1). Mortality rates can increase, be constant, or 
decrease over age. Demographers interpret increasing mortality rates 
at the population level as a manifestation of senescence at the organ-
ismal level. Likewise, they interpret constant or decreasing mortality 
rates as a manifestation of absent senescence (2–5). Senescence is a 
result of manifold biological mechanisms that lead to an increasing 
vulnerability to death. Although biologists have made strong effort 
at explaining and measuring senescence, the nature of these biologi-
cal mechanisms remains unclear and a reliable biomarker of senes-
cence is lacking (6,7). Moreover, it is continuously debated whether 
senescence and disease are distinct or related phenomena (4,8).
The rate of mortality can be regarded as a speed function: it 
expresses the number of deaths per unit of time comparably with the 
speed of a car that is expressed as the number of driven meters per 
unit of time. It follows that an increase in mortality rate corresponds 
with an acceleration of mortality, while a decrease in mortality rate 
corresponds with a deceleration of mortality, similar to the accelera-
tion or deceleration of the car (9,10). As senescence is represented 
by an increase in mortality rate over age, the rate of senescence can 
be calculated from the acceleration of mortality and is expressed as 
the increase in mortality rate per year of age (9,11). As an advantage 
to both demographers and biologists, this approach requires neither 
any assumptions on the age pattern of accelerations and decelera-
tions of mortality nor on the biological mechanisms underlying the 
process of senescence.
In this study, we describe and test a method to calculate the rate 
of senescence from age-specific mortality rates directly from non-
modeled mortality rates. This method can be used at all ages and is 
free of biological assumptions. It is purely based on the definition of 
senescence as the increase in mortality rate over age and calculates 
the rate of senescence as the acceleration of mortality over age. We 
apply this method to mortality data of patients with end-stage renal 
disease who are either on dialysis therapy or have undergone kid-
ney transplantation. Patients on dialysis therapy are biologically and 
clinically known to suffer from increased senescence rates (12–14). 
Mortality rates and senescence rates in patients with a functioning 
transplant are lower than in those on dialysis (15) and approach 
those of the general population (14).
Methods
Study Population
Data were provided by the Registry of the European Renal 
Association—European Dialysis and Transplant Association, which 
records the treatment and survival history of European patients 
receiving renal replacement therapy, either dialysis or kidney trans-
plantation (16). Patients were included when renal replacement ther-
apy was started during a period from 1985 through 2011. Follow-up 
ended on January 1, 2012. Individual patient data were available 
from 1985 for Austria, the French-speaking region of Belgium, 
Finland, Greece, Iceland, the Netherlands, Norway, and Scotland, 
from 1994 for the Flemish-speaking region of Belgium, from 1990 
for Denmark, from 2006 for Romania, from 1991 for Sweden, and 
from 1997 for England, Wales, and Northern Ireland. In addition, 
individual patient data were available for several regions in France 
from 2008, for several regions in Italy, including data from 2007 
for Abruzzo, Aosta Valley, Basilicata, Emilia-Romagna, Sardinia, 
Umbria, and Veneto and from 1997 for Calabria, and for several 
regions in Spain, including data from 1985 for Andalusia, from 2002 
for Aragon, from 1995 for Asturias, from 1992 for Basque Country, 
from 1985 for Catalonia, from 1994 for Cantabria, from 2003 for 
Castile-La Mancha, from 2002 for Castile and León, from 2005 for 
Extremadura, from 2007 for Galicia, and from 1992 for Valencia.
Mortality rates were calculated based on the follow-up data con-
tributed by each individual patient, separated for follow-up during 
dialysis and follow-up with a functioning transplant. For patients 
on dialysis, follow-up started 6  months after initiation of dialysis 
therapy, to account for early treatment-related mortality, and lasted 
until death, transplantation, recovery of renal function, loss to fol-
low-up, or censoring on January 1, 2012. For patients with a func-
tioning transplant, follow-up started 6 months after transplantation, 
to account for acute surgery-related mortality, and lasted until death, 
transfer to dialysis due to transplant failure, loss to follow-up, or 
censoring at January 1, 2012. For both treatment groups, the age-
specific mortality rates were derived by dividing the number of 
deaths by the years of follow-up per 5-year age group.
As a reference, mortality rates were also calculated for the gen-
eral European population. Numbers of deaths and population sizes 
were derived from Eurostat for the countries and regions included 
in this study (17). For each 5-year age group, the number of deaths 
was divided by the population size, both summed for the countries 
and regions and the years during which the countries and regions 
contributed data. As data were mostly available up to the age of 100, 
we excluded mortality rates from that age onward.
Estimating the Acceleration of Mortality Indirectly 
From the Parameters of Modeled Mortality Rates
To compare the use of non-modeled mortality rates with the use of 
modeled mortality rates, the mortality rates were modeled with the 
Gompertz model and senescence rates were estimated as previously 
described (14). Considering the applicability of the model, mor-
tality data were included for the ages of 20–85 years (14,18). The 
Gompertz model is mathematically described as m(t) = α eγ t, where 
m(t) is the mortality rate at age t in years and α and γ are model 
parameters. The minimal mortality rate at t = 0 is determined by α, 
the subsequent exponential increase by γ. On a logarithmical scale, 
the model conforms to a straight line, described by ln m(t) = ln α + 
γ t. The slope of this line is determined by γ, describes the accelera-
tion of mortality on the logarithmical scale, and estimates the rela-
tive senescence rate. The derivative function of the Gompertz model 
describes the acceleration of mortality on an absolute scale, esti-
mates the absolute senescence rate, and is mathematically described 
as m′(t) = α γ eγ t.
Calculating the Acceleration of Mortality Directly 
From Non-modeled Mortality Rates
The method proposed here calculates the absolute senescence rate 
directly from non-modeled mortality rates on an absolute scale. The 
method is based on the mathematical definition of a derivative func-
tion (19). In general, for a given function y  =  f(x), the derivative 
function is f′(x) = dy/dx, where d denotes an infinitesimal change in 
y or x. In the case of mortality rate m calculated for age t, the nota-
tions y and x are replaced: m′(t) = dm / dt. When we take d as small 
as possible, dt corresponds to the difference in age between two age 
groups and dm equals the difference in mortality rate between both 
age groups. Using this method, we calculate the rate at which the 
mortality rate changes, thus the acceleration of mortality, between 
two age groups on average. Applied, we calculated the senescence 
rate of an age group as the mortality rate of the following age group 
minus the mortality rate of the age group of interest, divided by 
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the difference in age between both age groups, the latter constantly 
being five years because of the use of 5-year age groups.
We excluded mortality rates from the analyses when the number 
of person-years was less than 200 per 5-year age group. Patients on 
dialysis aged 100 years and older were excluded, corresponding to 
less than 0.01% of follow-up and 0.01% of deaths. Patients with a 
functioning transplant aged 90 years and older were excluded, cor-
responding to 0.02% of follow-up and 0.05% of deaths. Due to the 
nature of this method, senescence rates could not be calculated for 
the oldest age group. It was not necessary to exclude mortality data 
for the youngest age groups.
Statistical Analyses
The calculations of the age-specific mortality rates were performed 
using IBM SPSS Statistics 20. The Gompertz model was fitted to the 
mortality data using Stata/SE 12.1, as previously described (14).
Results
Table 1 provides the general characteristics of the study population 
of patients with end-stage renal disease on dialysis or with a func-
tioning kidney transplant. As patients could successively undergo 
dialysis treatment and kidney transplantation, some patients con-
tributed follow-up to both treatment groups; this was the case for 
59,781 patients (18.8%) and 554,809 years of follow-up (41.5%). 
The maximum number of different treatment periods per patient 
was 13.
In Figure  1, the different methods to infer senescence rates 
from mortality rates are compared. For comparison with the 
method proposed here, we replicated the estimations of senescence 
rates from mortality data that were modeled by the Gompertz 
model, as described previously (14). Figure  1A and B show the 
modeled mortality rates over age on a logarithmical scale and the 
relative senescence rates estimated from the model’s parameters. 
According to this method, senescence rates were constant over 
age, lowest in patients on dialysis, intermediate in patients with 
a functioning transplant, and highest in the general population. 
Figure 1C and D show the modeled mortality rates over age on an 
absolute scale and the absolute senescence rates estimated from 
the model’s parameters. According to this method, senescence 
rates increased over age, were highest in patients on dialysis, inter-
mediate in patients with a functioning transplant, and lowest in 
the general population.
Figure 1E shows the crude non-modeled mortality rates over age 
on an absolute scale. For both patients on dialysis and patients with 
a functioning transplant, the exponential increase in mortality rates 
from age 20 to at least 70 provided visual justification for the appli-
cation of the Gompertz model. However, in both groups, at younger 
and older ages mortality rates deviated from the exponential increase 
and the Gompertz model was not applicable. Before age 20, mortality 
rates decreased over age. From age 70 to 90 onward, the exponential 
increase in mortality rates leveled off. At all ages, mortality rates were 
highest in patients on dialysis and lowest in the general population.
Figure  1F shows the absolute senescence rates as calculated 
directly from the non-modeled mortality rates by the method pro-
posed here. In contrast with the results obtained when using mod-
eled mortality rates, senescence rates could be calculated for all ages. 
From age 20 to approximately 70, the absolute senescence rates 
were comparable to those determined with the derivative function 
of the Gompertz model (Figure  1D). Using this direct calculation 
from non-modeled mortality rates, senescence rates were negative 
below the age of 5 and increased thereafter in the general popula-
tion. In patients with a functioning transplant, senescence rates were 
negative below the age of 20, then increased until the age of 75, after 
which they decreased to a similar level as in the general population. 
In patients on dialysis, senescence rates were negative below the age 
of 15 and were more pronounced than in patients with a functioning 
transplant and the general population. Above this age, their senes-
cence rates increased until the age of 90, after which they decreased 
to a lower level than in the general population.
Discussion
The aim of this study is to describe and empirically test a method for 
calculating the rate of senescence directly from non-modeled mortal-
ity rates. This method strictly follows the definition of senescence as 
the increase in mortality rate over age (2–5). In line with this defini-
tion, the method calculates the senescence rate as the acceleration of 
mortality over age, similar to the calculation of a derivative function. 
We validated our method by applying it to mortality data of patients 
with end-stage renal disease on dialysis, who are known to suffer 
from increased senescence rates, and of patients with a functioning 
kidney transplant, who have senescence rates that approach those 
of the general population. As an immediate advantage, this method 
yielded senescence rates for young and old ages that remained unre-
vealed when using modeled mortality rates.
Table 1. Characteristics of the Study Population of Patients With End-Stage Renal Disease
Characteristic Total On Dialysis With a Functioning Kidney Transplant
By number of patients
 Total number of patients, N 317,168 302,455 74,490
 Sex, % male 61.5 61.5 62.7
 Age, median years (iqr)
  At first treatment 64.1 (51.0–73.7) 65.0 (52.4–74.1) 48.6 (36.9–58.6)
  At death 72.2 (63.5–78.8) 73.1 (64.8–79.3) 63.5 (54.7–70.6)
 Follow-upper patient, median years (iqr) 2.7 (1.1–5.6) 2.0 (0.9–3.8) 5.4 (2.3–9.8)
By number of contributed years of follow-up
 Total years of follow-up, person-years (%) 1,337,832 841,109 (62.9) 496,723 (37.1)
 Sex, % male 60.6 59.8 62.0
Note: The total study population includes both patients on dialysis and patients with a functioning kidney transplant. As patients could successively undergo 
dialysis treatment and kidney transplantation, patients can be represented in both the group on dialysis and the group with a functioning transplant. iqr = inter-
quartile range.
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We compared the outcomes of different methods to determine 
senescence rates from mortality rates. Classically, mortality rates are 
modeled by the Gompertz model and subsequently presented on a 
logarithmical scale, rendering easily comparable straight lines over 
age of which the slopes are determined by a single parameter of the 
Gompertz model (Figure  1A). Senescence rates are derived from 
the increase in these lines and are thus fixed over age (Figure 1B) 
(2,20–22). Due to the logarithmical scale, this method estimates 
the senescence rate as the relative acceleration of mortality over 
age. However, it has been theoretically objected that the senescence 
rate should be defined as the absolute acceleration of mortality over 
age (11,23–25). According to this view, we have proposed to model 
mortality rates on an absolute scale (Figure  1C). Earlier, we have 
demonstrated that senescence rates can be more adequately derived 
from the absolute acceleration of mortality over age, using the deriv-
ative function of the Gompertz model (Figure 1D) (14). Contrary to 
the relative senescence rates, but in line with biological and clinical 
knowledge, the absolute senescence rates were highest in patients on 
dialysis and lowest in the general population. The principle of using 
the derivative function can be applied to any model of mortality 
over age.
Modeled mortality data are not always preferably used over 
crude mortality data. The ability of mathematical models to 
describe mortality is limited to a specific age range. The Gompertz 
model does not fit mortality rates at the youngest and oldest ages 
(18,26). This is explained by the fact that these models necessar-
ily mold mortality data into a prescribed pattern. The Gompertz 
model assumes mortality rates to increase exponentially over 
age (26). The mortality rates at the youngest and oldest ages in 
patients on dialysis and patients with a functioning transplant devi-
ated from an exponential increase over age, which became only 
apparent when assessing non-modeled mortality rates (Figure 1E). 
Models as the Gompertz model do not account for such deviating 
age patterns of mortality rates that may be valuable to measure, as 
will be discussed hereafter. Moreover, these models, which are by 
themselves of only mathematical nature, are mistakenly interpreted 
biologically (26–28). Apart from the Gompertz model, the Weibull 
model and the logistic model are often used without any of them 
superiorly fitting mortality curves over age. The choice of a model 
is consequently based on biological assumptions explaining the age 
pattern that is imposed on the rates by the model (26,29). As we 
have shown previously (14), such a biological meaning is gener-
ally attributed to the mathematical parameters of the Gompertz 
model, but has no empirical foundation and is biologically invalid 
(11,23–25). An alternative method has been proposed to calcu-
late senescence rates from non-modeled mortality rates, but only 
on a logarithmical scale, thus rendering relative senescence rates 
(30,31).
Here we extended our earlier analyses by applying a method that 
circumvents the need to first model mortality rates for the calcula-
tion of senescence rates on an absolute scale (Figure 1E and F). From 
age 20 to approximately 70, the senescence rates calculated by this 
method were similar to those estimated by the derivative function of 
the Gompertz model. However, this method additionally offers the 
possibility to calculate senescence rates for young and old ages that 
are unaccounted for by the Gompertz model.
Figure  1. A comparison of different methods to infer senescence rates from mortality rates. This overview shows different methods that use age-specific 
mortality rates (A, C, E) to calculate senescence rates (B, D, F), including the classical method (A, B), a method as proposed earlier by us (C, D), and a method 
presented in this article (E, F). The methods were applied to patients with end-stage renal disease on dialysis therapy and with a functioning kidney transplant 
and to the general population, as explained in the text.
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At young ages, the method proposed here disclosed negative senes-
cence rates. Senescence rates were more negative in patients on dialy-
sis than in patients with a functioning transplant and in the general 
population. Negative senescence rates at young ages have not been 
frequently addressed for humans, as changes in mortality are mainly 
studied from adolescence onward. For several non-human species it 
has been recognized that mortality rates decline during life, a finding 
which has been termed negative senescence (32). At the beginning of 
human life, negative senescence is universally observed as a decline in 
mortality rate caused by processes that are distinct from senescence. 
It may be the result of a reduction in children’s vulnerability during 
development and growth or of a reduction in a population’s vulner-
ability due to the early death of the frailest children and the selective 
survival of healthier children (33,34). In the cases of dialysis therapy 
(35) and kidney transplantation (36), development and growth are 
impaired in children, although the deficits are partly compensated 
at a later age. The negative senescence rates in both groups more 
likely arise from a sharp decline in mortality rate due to early death 
of the frailest patients and the selective survival of healthier patients. 
Particularly in the youngest patients, mortality rates are high due to 
the underlying renal disease, congenital disorders that are associated 
with pediatric renal disease, and the complications of dialysis therapy 
or transplantation (37–39). The more negative senescence rates in 
children on dialysis compared with children with a functioning trans-
plant and the general population can be explained as they display 
higher mortality rates at the youngest ages with a subsequent sharper 
decline in mortality and improved growth. In addition, their negative 
senescence rates may be more pronounced due to a stronger effect of 
selective survival of the less frail patients: as those selected for trans-
plantation are relatively healthier (38), the survival probabilities of 
children admitted to dialysis vary more than those of children under-
going kidney transplantation and in the general population. Negative 
senescence early in life has received little attention of gerontologists, 
but interacts closely with senescence later in life (34). It would be 
interesting to include the age at which negative senescence rates turn 
into positive rates in studies on senescence. Comparable turning 
points in the age pattern of senescence rates have been studied, but 
only at older ages (40).
At old ages, the method proposed here uncovered declining 
senescence rates that are not accounted for by many models. The 
phenomenon of leveling mortality rates, and thus declining senes-
cence rates, at old ages has been described in different populations 
(2,41). Heterogeneity in survival patterns due to individual differ-
ences in frailty is thought to bring about leveling mortality rates 
(42). In selected homogeneous populations, mortality rates continue 
to increase exponentially up to the oldest ages (43). The decline in 
senescence rates in patients on dialysis and patients with a func-
tioning transplant can be explained by the selective survival to the 
older ages of the relatively healthier patients and by the selection of 
relatively healthier patients to undergo these therapies at older ages. 
That the senescence rates in patients with a functioning transplant 
declined at younger ages compared with patients on dialysis suggests 
that these selective processes are stronger in this group, probably 
because of the reluctance to perform kidney transplantation in older 
patients. Senescence rates in the general population did not decrease, 
probably because heterogeneity effects emerge at older ages in large 
populations with low senescence rates (2,41). The method proposed 
here can be applied to further study declines in senescence rates in 
populations at the oldest ages.
This study investigated methods that determine senescence rates 
at the population level. The senescence rate of an individual cannot 
be inferred directly from the senescence rate of the population to 
which he belongs (24). Still, the increased senescence rates in patients 
on dialysis can be attributed to biological and clinical mechanisms 
that have been observed and promote senescence in the individual 
patients (8,44). In patients with end-stage renal disease as well as in 
older people in the general population, podocytes lining the epithe-
lium of glomeruli show signs of damage and dysfunction, resulting 
in glomerulosclerosis and reduced glomerular filtration (45). Renal 
dysfunction causes accumulation of mineral and uremic toxins, oxi-
dative stress, and systemic inflammation, which are normally seen 
at old ages. These processes promote cellular senescence through 
DNA damage, mitochondrial dysfunction, and telomere shortening. 
Widespread cellular injury and dysfunction lead to increased risks 
and rates of atherosclerosis, cardiac disease, cancer, immune defi-
ciency, cognitive impairment, sarcopenia, and osteoporosis. These 
disorders, together with dialysis therapy itself, again induce further 
hemodynamic and immunological disturbances and loss of renal 
function. Eventually, these disorders lead to increased mortality rates 
(12,13,45,46). The method proposed here can be applied to compare 
the senescence rates of different populations, to identify populations 
with increased or decreased senescence rates, and to evaluate the 
effects of interventions on the senescence rate.
The method presented here has several advantages. As it does not 
use modeled mortality rates, it can be applied to any mortality data, 
at all ages, and independent of species, geographic origin, calendar 
period, and birth cohort. As it does not mold the mortality rates into 
a prescribed pattern, it closely follows the crude mortality data, does 
not discard any mortality data, and is very sensitive to changes in 
the senescence rate. Particularly those patterns of mortality that are 
not predicted by models may be informative about the process of 
senescence, as illustrated earlier for young and old ages. Finally, as 
this method is free of assumptions about the mortality patterns over 
age or the biological determinants underlying these patterns, it can 
only be interpreted based on its mathematical meaning. It measures 
the acceleration of mortality over age and thereby, given the defini-
tion of senescence as the increase in mortality rate over age, describes 
the senescence rate.
The use of non-modeled mortality data for the calculation of the 
senescence rate also has disadvantages. First, substantial amounts 
of age-specific crude data are required to prevent high variability 
in the estimates due to measurement error. Although large cohorts 
were available in this study, the senescence curves that were calcu-
lated with the proposed method show more variability than those 
calculated with the Gompertz model. We excluded age groups with 
few observations; each of these comprised less than 25 person-years 
of follow-up. Each age group included in the study comprised more 
than 200 person-years of follow-up. It is difficult to determine a level 
above which variability is unacceptably high. We cannot distinguish 
whether variability has arisen from measurement error or real age-
related effects, which are both suppressed by modeling. Much of the 
variability depends on the width of the age groups for which the 
mortality rates have been calculated. This width can be adjusted in 
this method to reduce the effect of data variability. This reduction 
in variability will probably render the senescence rates more simi-
lar to those calculated from modeled mortality data. Furthermore, 
this method can be extended with techniques to smoothen the senes-
cence curves, but that again introduces modeling based on statisti-
cal or biological assumptions. Second, the senescence rate can only 
be determined for those age groups with available mortality data. 
Without a model of mortality over age, extrapolation to other ages 
is not possible.
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In conclusion, this study shows how the absolute rate of senes-
cence can be calculated directly from age-specific non-modeled 
mortality rates. The methodology is simple, sensitive to changes 
in mortality over age, free of limitations in its applicability, and 
does not require any biological interpretation of mathematical 
models.
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and I. Moina), Cantabria (M. Arias Rodríguez and O. García Ruiz), Castile 
and León (R. González and C.  García-Renedo), Castile-La Mancha (G. 
Gutiérrez Ávila and I. Moreno Alía), Catalonia (RMRC) (E. Arcos, J. Comas, 
and P.A. Montserrat), Extremadura (J.M. Ramos Aceitero and M.A. García 
Bazaga), Galicia (E. Bouzas-Caamaño and J. Sánchez-Ibáñez), and Valencian 
region (REMRENAL) (O. Zurriaga Llorens and M. Ferrer Alamar); and the 
other ERA-EDTA registry committee members for their advice in the analysis 
and the drafting of this paper: R. Vanholder, C. Wanner, F.J. Caskey, F. Collart, 
C.  Couchoud, D.  Fouque, J.W. Groothoff, J.G. Heaf, P.  Ravani, I.  Rychlik, 
F. Schaefer, and S. Schön.
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